Endocrinology Diabetes and Metabolism Case Reports · 2015 · 13 citations · 8 references
MedicineEndocrinologyOncologyEndocrine OncologyEndocrine PharmacotherapyGastrointestinal OncologyEndocrine DiseaseEndocrine DisordersEndocrine TumorsHormone-secreting TumorsNeuroendocrine DisordersNeuroendocrine TumorsEndocrine HypersecretionEnteroendocrine CellsGlucagon BiosynthesisGlucagon ProcessingGlucagon-like Peptide 1 SignalingGlucagon-like PeptidesPancreatic Endocrine DisordersPancreatic Neuroendocrine Neoplasms
UNLABELLED: Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman presented with necrolytic migratory erythema, anorexia, constipation and hyperinsulinaemic hypoglycaemia. She was found to have a grade 1 pNET, small bowel mucosal thickening and hyperglucagonaemia. Somatostatin analogue (SSA) therapy improved appetite, abolished hypoglycaemia and improved the rash. Case 2, a 48-year-old male presented with diabetes mellitus, diarrhoea, weight loss, nausea, vomiting and perineal rash due to a grade 1 metastatic pNET and hyperglucagonaemia. In both cases, plasma levels of all measured PGDPs were elevated and attenuated following SSA therapy. In case 1, there was increased production of intact glucagon-like peptide 1 (GLP-1) and GLP-2, similar to that of the enteroendocrine L cell. In case 2, pancreatic glucagon was elevated due to a pancreatic α-cell-like proglucagon processing profile. In summary, we describe two patients with pNETs and heterogeneous clinical phenotypes due to differential processing and secretion of PGDPs. This is the first description of a patient with symptomatic hyperinsulinaemic hypoglycaemia and marked gastrointestinal dysfunction due to, in part, a proglucagon-expressing pNET. LEARNING POINTS: PGDPs exhibit a diverse range of biological activities including critical roles in glucose and amino acid metabolism, energy homeostasis and gastrointestinal physiology.The clinical manifestations of proglucagon-expressing tumours may exhibit marked phenotypic variation due to the biochemical heterogeneity of their secreted peptide repertoire.Specific and precise biochemical assessment of individuals with proglucagon-expressing tumours may provide opportunities for improved diagnosis and clinical management.
8
Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
Michael Gleeson, S.R. Bloom, J. M. Polak et al. · Gut · 1971 · 382 citations · Full text
Medicine, Endocrinology, Oncology +16